person · Reporting owner
Redmont VAXN Capital Holdings, LLC
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Altimmune, Inc.ALT · Entity 5349 | Director | October 13, 2017 | October 17, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Altimmune, Inc.
Report date October 13, 2017 · Filed October 17, 2017
Jointly reported with Hodges Philip
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001SEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2017-10-17 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2017-10-17 · Other · Disposed 1,278,471 · Balance 0 F1: Redmont VAXN Capital Holdings, LLC, a Delaware limited liability company ("Redmont VAXN") distributed to its members, pro rata and without consideration, 1,278,471 shares of the Issuer's common stock. F2: Consists of shares of Common Stock held by Redmont VAXN. Philip Hodges has sole voting and dispositive control with respect to all securities held by Redmont VAXN. Philip Hodges disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. |
| Stock Options (option to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.50 · Expires 2027-10-13 | Direct | 20,000 |
Reported balance
After 2017-10-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-10-13 · Grant · Acquired 20,000 · Balance 20,000 F3: Held by Philip Hodges. |
Filing footnotes · ownership attribution and instrument terms
F1: Redmont VAXN Capital Holdings, LLC, a Delaware limited liability company ("Redmont VAXN") distributed to its members, pro rata and without consideration, 1,278,471 shares of the Issuer's common stock.
F2: Consists of shares of Common Stock held by Redmont VAXN. Philip Hodges has sole voting and dispositive control with respect to all securities held by Redmont VAXN. Philip Hodges disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein.
F3: Held by Philip Hodges.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 17, 2017 Filed Oct 17, 2017 20:04 UTC | Altimmune, Inc. ALT · Entity 5349 | OtherCommon Stock, par value $0.0001 | 1,278,471 | $0.00 | $0.00 |
DisclosureSEC source: 0001012975-17-000759 · edgar.xml · nonDerivative · entry 1 Hodges Philip · CIK 0001705562 · Director Redmont VAXN Capital Holdings, LLC · CIK 0001705638 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 F1 · kind: Redmont VAXN Capital Holdings, LLC, a Delaware limited liability company ("Redmont VAXN") distributed to its members, pro rata and without consideration, 1,278,471 shares of the Issuer's common stock. F2 · ownership.nature: Consists of shares of Common Stock held by Redmont VAXN. Philip Hodges has sole voting and dispositive control with respect to all securities held by Redmont VAXN. Philip Hodges disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Read SEC document |
| October 13, 2017 Filed Oct 17, 2017 20:04 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 20,000 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001012975-17-000759 · edgar.xml · derivative · entry 2 Hodges Philip · CIK 0001705562 · Director Redmont VAXN Capital Holdings, LLC · CIK 0001705638 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock, par value $0.0001 · 20,000 shares Expires 2027-10-13 F3 · ownership.direct: Held by Philip Hodges. Read SEC document |
| May 04, 2017 Filed May 8, 2017 20:37 UTC | Altimmune, Inc. NASDAQ:ALT · Entity 5349 | GrantCommon Stock, par value $0.0001 | 4,455 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-012362 · doc4.xml · nonDerivative · entry 3 Hodges Philip · CIK 0001705562 · Director Redmont VAXN Capital Holdings, LLC · CIK 0001705638 · 10% owner Redmont Venture Partners, Inc. · CIK 0001705639 · 10% owner Paradigm Venture Partners, L.P. · CIK 0001705640 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 4,455 F1 · price: Acquired pursuant to the Agreement and Plan of Merger, dated as of January 18, 2017 (as amended on March 29, 2017, the "Merger Agreement"), pursuant to which a wholly-owned subsidiary of the Issuer merged with and into Altimmune, Inc. ("Altimmune"). Pursuant to the Merger Agreement, the then outstanding shares of Altimmune's capital stock was converted into the right to receive a number of shares of the Issuer's common stock, par value $0.0001 on a 0.749106:1 basis upon the closing of the merger. F4 · ownership.nature: Consists of shares of Common Stock held by Paradigm Venture Partners, L.P., a Delaware limited partnership ("PVP"). Mr. Hodges has sole voting and dispositive control with respect to all securities held by PVP. Mr. Hodges disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Read SEC document |
| May 04, 2017 Filed May 8, 2017 20:37 UTC | Altimmune, Inc. NASDAQ:ALT · Entity 5349 | GrantCommon Stock, par value $0.0001 | 36,785 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-012362 · doc4.xml · nonDerivative · entry 2 Hodges Philip · CIK 0001705562 · Director Redmont VAXN Capital Holdings, LLC · CIK 0001705638 · 10% owner Redmont Venture Partners, Inc. · CIK 0001705639 · 10% owner Paradigm Venture Partners, L.P. · CIK 0001705640 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 36,785 F1 · price: Acquired pursuant to the Agreement and Plan of Merger, dated as of January 18, 2017 (as amended on March 29, 2017, the "Merger Agreement"), pursuant to which a wholly-owned subsidiary of the Issuer merged with and into Altimmune, Inc. ("Altimmune"). Pursuant to the Merger Agreement, the then outstanding shares of Altimmune's capital stock was converted into the right to receive a number of shares of the Issuer's common stock, par value $0.0001 on a 0.749106:1 basis upon the closing of the merger. F3 · ownership.nature: Consists of shares of Common Stock held by Redmont Venture Partners, Inc., a Delaware corporation ("RVP"). Mr. Hodges has sole voting and dispositive control with respect to all securities held by RVP. Mr. Hodges disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Read SEC document |
| May 04, 2017 Filed May 8, 2017 20:37 UTC | Altimmune, Inc. NASDAQ:ALT · Entity 5349 | GrantCommon Stock, par value $0.0001 | 1,278,471 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-17-012362 · doc4.xml · nonDerivative · entry 1 Hodges Philip · CIK 0001705562 · Director Redmont VAXN Capital Holdings, LLC · CIK 0001705638 · 10% owner Redmont Venture Partners, Inc. · CIK 0001705639 · 10% owner Paradigm Venture Partners, L.P. · CIK 0001705640 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,278,471 F1 · price: Acquired pursuant to the Agreement and Plan of Merger, dated as of January 18, 2017 (as amended on March 29, 2017, the "Merger Agreement"), pursuant to which a wholly-owned subsidiary of the Issuer merged with and into Altimmune, Inc. ("Altimmune"). Pursuant to the Merger Agreement, the then outstanding shares of Altimmune's capital stock was converted into the right to receive a number of shares of the Issuer's common stock, par value $0.0001 on a 0.749106:1 basis upon the closing of the merger. F2 · ownership.nature: Consists of shares of Common Stock held by Redmont VAXN Capital Holdings, LLC, a Delaware limited liability company ("RVCH"). Philip Hodges has sole voting and dispositive control with respect to all securities held by RVCH. Mr. Hodges disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.